Business Context and Reporting Period
Company: CURIS, INC. (CRIS)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2024
Business Overview: Curis is a biotechnology company focused on developing emavusertib (CA-4948), an IRAK4 inhibitor for hematologic malignancies. The company also holds a collaboration with Genentech/Roche for royalties on Erivedge (vismodegib). In May 2024, the company streamlined operations, reducing its workforce by approximately 30% to focus on key clinical trials.
Key Financial Metrics
| Metric (in thousands) | Q2 2024 | Q2 2023 | 6 Months 2024 | 6 Months 2023 |
|---|---|---|---|---|
| Revenues, net | $2,546 | $2,197 | $4,632 | $4,494 |
| Net Loss | $(11,803) | $(11,961) | $(23,679) | $(23,520) |
| Loss per Share (Basic/Diluted) | $(2.03) | $(2.47) | $(4.08) | $(4.87) |
| Operating Cash Flow | N/A | N/A | $(24,367) | $(20,067) |
| Cash & Investments (Total) | $28.4 million (as of June 30, 2024) | |||
| Accumulated Deficit | $(1.22 billion) (as of June 30, 2024) |
Liquidity: As of June 30, 2024, the company held $9.996 million in cash and cash equivalents and $18.364 million in short-term investments. Total current liabilities were $19.366 million.
Material Changes vs. Prior Period
- Revenue Growth: Net revenue increased 16% in Q2 2024 compared to Q2 2023, driven by royalties from Erivedge sales.
- Expense Management: Research and Development (R&D) expenses increased slightly (2% in Q2, 4% for six months) primarily due to severance costs from the May 2024 workforce reduction, partially offset by lower consulting costs. General and Administrative (G&A) expenses increased 13% in Q2, also driven by severance.
- Other Income: Other income increased significantly (301% in Q2) due to a decrease in non-cash expense related to the sale of future royalties.
- Balance Sheet: Total assets decreased from $77.3 million (Dec 31, 2023) to $50.4 million (June 30, 2024), reflecting a reduction in cash and investments. Stockholders' equity moved from a positive $19.7 million to a deficit of $(0.7) million.
Outlook, Risks, and Contingencies
Going Concern Warning: The company has identified conditions raising substantial doubt about its ability to continue as a going concern. Management estimates current cash and investments will fund operations only into the first quarter of 2025. Additional financing is required to continue operations and clinical development.
Clinical Pipeline:
- TakeAim Leukemia: Phase 1/2 study for relapsed/refractory AML and high-risk MDS. Additional data expected late 2024.
- TakeAim Lymphoma: Phase 1/2 study for PCNSL in combination with ibrutinib. Additional data expected late 2024.
- AML Triplet Study: Phase 1 safety study of emavusertib with azacitidine and venetoclax. Initial safety data expected late 2024.
Material Contingency (Oberland Purchase Agreement):
- In March 2023, counsel for the Purchasers (Oberland Capital) alleged defaults under the royalty sale agreement and demanded cure. Curis disputes these allegations.
- If the Purchasers exercise their put option, Curis may be required to repurchase royalty rights at a "Put/Call Price" estimated at $46.5 million as of June 30, 2024.
- Failure to resolve this or secure funding could materially harm the company's financial condition and ability to continue operations.
Financing: The company has an "at-the-market" sales agreement with Cantor Fitzgerald and JonesTrading. $99.8 million of shares remained available for sale as of June 30, 2024.
Investor Verification Checklist
- Cash Runway: Verify the timeline for the next capital raise given the Q1 2025 liquidity horizon.
- Oberland Dispute: Monitor for any updates regarding the alleged defaults and potential exercise of the put option ($46.5M liability).
- Clinical Data: Watch for late 2024 data releases from the TakeAim Leukemia, TakeAim Lymphoma, and AML Triplet studies.
- Workforce Reduction: Assess the long-term impact of the 30% workforce reduction on development timelines.
- Stock Dilution: Track share issuances under the 2024 Sales Agreement and potential future equity financings.